The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients

Kidney International

Volumn 66, Issue 1, 2004, Pages 367-374

  Grossman, Eric B ^a   Swan, Suzanne K ^b   Muirhead, Gary J ^b   Gaffney, Michael ^b   Chung, Menger ^b   DeRiesthal, Herb ^b   Chow, Diane ^b   Raij, Leopoldo ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

Hemodialysis; Hemodynamics; Pharmacokinetics; Renal disease; Sildenafil citrate

Indexed keywords

DRUG METABOLITE; SILDENAFIL; UK 103320; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; ERECTILE DYSFUNCTION; HEMODIALYSIS; HEMODYNAMICS; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 3042848827     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00739.x     Document Type: Article

References (31)

1. SOLOMON H, MAN JW, JACKSON G: Erectile dysfunction and the cardiovascular patient: Endothelial dysfunction is the common denominator. Heart 89:251-253, 2003
2. LUE TF: Erectile dysfunction. N Engl J Med 342:1802-1813, 2000
3. LAWRENCE IG, PRICE DE, HOWLETT TA, et al: Correcting impotence in the male dialysis patient: Experience with testosterone replacement and vacuum tumescence therapy. Am J Kidney Dis 31:313-319, 1998
4. ROSAS S, JOFFE M, FRANKLIN E, et al: Prevalence and determinants of erectile dysfunction in hemodialysis patients. Kidney Int 59:2259-2266, 2001
5. PROCCI WR, MARTIN DJ: Effect of maintenance hemodialysis on male sexual performance. J Nerv Ment Dis 173:366-372, 1985
6. FOULKS CJ, CUSHNER HM: Sexual dysfunction in the male dialysis patient: Pathogenesis, evaluation, and therapy. Am J Kidney Dis 8:211-222, 1986
7. ROSAS SE, JOFFE M, FRANKLIN E, et al: Association of decreased quality of life and erectile dysfunction in hemodialysis patients. Kidney Int 64:232-238, 2003
8. YENICERIOGLU Y, KEFI A, ASLAN G, et al: Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis. BJU Int 90:442-445, 2002
9. CHEN J, MABJEESH NJ, GREENSTEIN A, et al: Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol 165:819-821, 2001
10. ROSAS SE, WASSERSTEIN A, KOBRIN S, FELDMAN HI: Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. Am J Kidney Dis 37:134-137, 2001
11. NICHOLS DJ, MUIRHEAD GJ, HARNESS JA: Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53:5S-12S, 2002
12. MUIRHEAD GJ, WILNER K, COLBURN W, et al: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br J Clin Pharmacol 53:21S-30S, 2002
13. MUIRHEAD GJ, RANCE DJ, WALKER DK, WASTALL P: Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 53(Suppl 1):13S-20S, 2002
14. LANGTRY H, MARHAM A: Sildenafil: A review of its use in erectile dysfunction. Drugs 57:967-989, 1999
15. BALLARD SA, GINGELL CJ, TANG K, et al: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164-2171, 1998
16. JEREMY JY, BALLARD SA, NAYLOR AM, et al: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79:958-963, 1997
17. NISHIMURA M, TAKAHASHI H, MARUYAMA K, et al: Enhanced production of nitric oxide may be involved in acute hypotension during maintenance hemodialysis. Am J Kidney Dis 31:809-817, 1998
18. NISHIMURA M, TAKAHASHI H, YOSHIMURA M: Role of nitric oxide in haemodialysis hypotension. Acta Physiol Scand 168:181-186, 2000
19. RYSZ J, LUCIAK M, KEDZIORA J, et al: Nitric oxide release in the peripheral blood during hemodialysis. Kidney Int 51:294-300, 1997
20. YOKOKAWA K, MANKUS R, SAKLAYEN MG, et al: Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med 123:35-37, 1995
21. RAJ DS, VINCENT B, SIMPSON K, et al: Hemodynamic changes during hemodialysis: Role of nitric oxide and endothelin. Kidney Int 61:697-704, 2002
22. BOOLELL M, ALLEN MJ, BALLARD SA, et al: Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52, 1996
23. Metropolitan Life Insurance Company Standards (Men/Women), New York, NY, Metropolitan Life Insurance Company, 1996
24. COOPER KL, MCKIERNAN JM, KAPLAN SA: Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 57:9-17, 1999
25. LEE CS, MARBURY TC: Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet 9:42-66, 1984
26. VARDI Y, KLEIN L, NASSAR S, et al: Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 59:747-752, 2002
27. MACDONALD NJ, GRANT AC, RODGER RS, et al: The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol. Br J Clin Pharmacol 31:697-700, 1991
28. CHAIGNON M, CHEN WT, TARAZI RC, et al: Blood pressure response to hemodialysis. Hypertension 3:333-339, 1981
29. DAUGIRDAS JT: Dialysis hypotension: A hemodynamic analysis. Kidney Int 39:233-246, 1991
30. MOHAMED EA, MACDOWALL P, COWARD RA: Timing of sildenafil therapy in dialysis patients - Lessons following an episode of hypotension. Nephrol Dial Transplant 15:926-927, 2000
31. SIEGEL R, GROSSMAN E: Timing of sildenafil therapy in dialysis patients. Nephrol Dial Transplant 16:1719-1720, 2001